PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Operating Expenses

Last Annual Value

92.22M

3-Year CAGR

11%

5-Year CAGR

118%

10-Year CAGR

54%

PepGen Inc.

PepGen Inc. Competitors Analysis of Operating Expenses

PEPG · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
92.22M
3.3%27.7%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
157.19M
-13.2%23.4%26.0%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
112.01M
-3.8%5.3%N/A
104.75M
12.0%-0.2%N/A
22.50M
-3.4%N/AN/A
65.70M
20.2%40.2%N/A
132.46M
-4.5%0.7%N/A
27.57M
6.4%16.4%N/A
52.37M
-31.0%-19.6%N/A
95.39M
79.4%23.8%20.4%
85.31M
23.7%9.1%14.6%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642